Covance Opens New Clinical Development Offices in Brazil and Mexico
- Broader Latin American presence increases access to patients to help reduce drug development timelines -
PRINCETON, N.J., Sept. 9 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE: CVD) today announced the opening of new clinical development offices in Sao Paolo, Brazil and Mexico City, Mexico. These offices further expand Covance's global footprint with a comprehensive range of services across Latin America. Earlier this year, Covance announced new offices in Santiago, Chile and Lima, Peru. These new sites will support staff in these countries, Central America, and the Caribbean, as well as the regional network of field-based clinical research associates in the region.
Covance has been providing clinical trial support in Latin America since 1997 with the company's first office in Buenos Aires, Argentina. Operations in the region expanded quickly through a network of regional clinical trial monitors trained and supervised under guidelines meeting both local and international regulatory requirements as well as global Covance quality standards.
"Our continued expansion in Latin America highlights the region's growing significance in Covance's clinical development service offerings. These new offices increase our access to patients who are currently not receiving medical therapies and will enable us to shorten clinical trial cycle times for our pharmaceutical and biotech clients," said Wayne Langlois, vice president and general manager of global clinical development services at Covance.
"The clinical trials we conduct in Latin America are part of a carefully weighted site selection approach that not only produces high-quality data on time, but also satisfies the requirements of regulatory authorities," said Katie Margules, senior director for Latin America.
Covance offers clinical development services for Phase I to III clinical trials in more than 55 countries which include emerging markets across Asia Pacific, Central and Eastern Europe, and Latin America. With a full suite of services to take a drug through all stages of development, Covance offers extensive clinical and therapeutic expertise, global reach, proactive project management, and strong investigator site relationships to consistently deliver high quality data on time.
Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.7 billion, global operations in more than 25 countries, and more than 10,000 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com.
Statements contained in this press release, which are not historical facts, are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, levels of industry research and development spending, the Company's ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss of large contracts, and other factors described in the Company's filings with the Securities and Exchange Commission.